Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT06195306
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Atypical Hyperplasia
- Breast Carcinoma
- Breast Ductal Carcinoma In Situ
- Breast Lobular Carcinoma In Situ
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 45 to 74 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- National Cancer Institute (NCI)
- Last updated on ClinicalTrials.gov
- August 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Kansas · 1
- University of Kansas Cancer Center · Kansas City, KS
Michigan · 1
- University of Michigan Rogel Cancer Center · Ann Arbor, MI
Ohio · 1
- Ohio State University Comprehensive Cancer Center · Columbus, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.